NEW YORK (GenomeWeb News) — MorphoSys today said fourth-quarter revenues increased 44 percent as operating expenses, coming largely from R&D, spiked 115 percent and profit turned to a loss.
 
Total receipts for the three months ended Dec. 31, 2006, increased to €14 million ($18.5 million) from €9.7 million year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.